Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 113

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 113
---
 us to fund our operations through March 31, 2027.

Through December 31, 2024,
we have financed our operations primarily through private placements, convertible loans and short-term loans. Total invested capital
as of December 31, 2024 was $35.7 million, which included Ordinary Shares, Preferred Shares and warrants to purchase Preferred Shares.

The following table summarizes
our statement of cash flows for the years ended December 31, 2024 and 2023:

|                                                  | (U.S. dollars in thousands except share and per share data) | For the Years Ended 
 December            
 31,                 | 2024 |   |     |     |   2023 |   |
|:-------------------------------------------------|:------------------------------------------------------------|:--------------------|-----:|:--|:----|:----|-------:|:--|
| Net cash used in operating activities            |                                                             | $                   | (641 | ) |     |     | (1,220 |   |
| Net cash used in investing activities            |                                                             |                     |    - |   |     |     |      - |   |
| Net cash provided by financing activities        |                                                             |                     |  525 |   |     |     |    325 |   |
| (Decrease) Increase in cash and cash equivalents |                                                             | $                   | (116 | ) |     |     |   (895 | ) |

<div align='center'>66</div>

Net cash used in operating activities

Net cash provided by (used in) operating activities

Net cash used in operating
activities for the year ended December 31, 2024 was $0.6 million, compared to $1.2 million for in 2023. This decrease is mainly due to
receipt of approval from EASME in April 2024.

Net cash used in investing activities

There were no net cash
used in investing activities during the years ended December 31, 2024 and 2023.

Net cash used in financing activities

Net cash provided by financing
activities increased by $0.2 million, to approximately $0.5 million for the year ended December 31, 2024 compared to $0.3 million for
the year ended December 31, 2023. This increase was due to higher proceeds from short-term loan in 2024.

Funding Requirements

We have incurred losses
from operations since the inception, resulting in an accumulated deficit on December